Summit Therapeutics (NASDAQ:SMMT) stock spikes as Citi upgrades the company, citing its lead asset ivonescimab, developed ...

Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, ...

Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study ...

Vision loss is a growing concern in India, especially macular degeneration - a common eye condition. Once known to be ...

HC Wainwright downgraded shares of Opthea (NASDAQ:OPT – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, MarketBeat.com reports. The firm currently ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

The capability of the VSMCs to react to hypoxic stimuli was assessed by intracellular calcium and ATP measurements and by VEGF mRNA expression analysis. VSMCs respond to hypoxia with decreases in ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

The following is a summary of “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration,” published in the March 2025 issue of British Journal ...

Oppenheimer lowered shares of Opthea (NASDAQ:OPT – Free Report) from an outperform rating to a market perform rating in a research report released on Monday, MarketBeat reports. A number of other ...